Compare CREG & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | GDTC |
|---|---|---|
| Founded | N/A | 2018 |
| Country | China | Singapore |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.4M |
| IPO Year | 2019 | 2021 |
| Metric | CREG | GDTC |
|---|---|---|
| Price | $2.22 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 18.7K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,509.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.68 |
| 52 Week High | $3.03 | $3.68 |
| Indicator | CREG | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 68.73 | 52.21 |
| Support Level | $1.08 | $0.94 |
| Resistance Level | $2.23 | $1.25 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 69.47 | 52.62 |
Smart Powerr Corp is engaged in waste energy recycling and is a developer of energy efficiency solutions for various energy intensive industries in China. It uses Build-Operate-Transfer (BOT) model to provide energy saving and recovery facilities for multiple energy intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. It provides a clean-technology and energy-efficient solution aimed at reducing the air pollution and energy shortage problems in China. The company's operations are conducted in one industry segment. All of its assets are located in the PRC.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.